日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial

恩沙替尼与克唑替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌患者的随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2021.3523
Horn, Leora; Wang, Ziping; Wu, Gang; Poddubskaya, Elena; Mok, Tony; Reck, Martin; Wakelee, Heather; Chiappori, Alberto A; Lee, Dae Ho; Breder, Valeriy; Orlov, Sergey; Cicin, Irfan; Cheng, Ying; Liu, Yunpeng; Fan, Yun; Whisenant, Jennifer G; Zhou, Yi; Oertel, Vance; Harrow, Kim; Liang, Chris; Mao, Li; Selvaggi, Giovanni; Wu, Yi-Long
肺癌
肿瘤
肿瘤免疫
信号转导
淋巴瘤
细胞生物学
发表日期：2021
文献求助 收藏

Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

一项评估沃罗拉尼在晚期实体瘤患者中安全性、耐受性和药代动力学的I期、首次人体剂量递增研究

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2018-0740
Bendell, Johanna C; Patel, Manish R; Moore, Kathleen N; Chua, Cynthia C; Arkenau, Hendrik-Tobias; Dukart, Gary; Harrow, Kim; Liang, Chris
Human
发表日期：2019
文献求助 收藏

Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.

使用 FLT PET/CT 对采用 X-82 和多西他赛序贯联合治疗的晚期实体恶性肿瘤进行药效学研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-018-3599-3
Scarpelli Matthew, Rampurwala Murtuza, Eickhoff Jens, Carmichael Lakeesha, Heideman Jennifer, Binger Kimberly, Kolesar Jill, Perlman Scott, Harrow Kim, Dukart Gary, Liang Chris, Jeraj Robert, Liu Glenn, Bruce Justine Yang
肿瘤
肿瘤免疫
发表日期：2018
文献求助 收藏